OPR - Delayed Quote • USD KMDA Aug 2024 10.000 call (KMDA240816C00010000) Follow 0.2000 0.0000 (0.00%) As of April 17 at 10:23 AM EDT. Market Open. Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for KMDA240816C00010000 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: KMDA KMDA: Double Digit Growth Anticipated in 2024 with $158 Million in Expected Revenues and $28 Million in Expected Adjusted EBITDA… Kamada Ltd. (NASDAQ:KMDA) Q4 2023 Earnings Call Transcript Kamada Issues 2024 CEO Letter to Shareholders Kamada Reports Strong Fiscal Year and Fourth Quarter 2023 Financial Results, and Provides Full-Year 2024 Guidance Representing Double-Digit Growth in Revenue and Profitability Kamada to Announce Fourth Quarter and Fiscal Year 2023 Financial Results, and Provide 2024 Financial Guidance on March 6, 2024 KEDRION ANNOUNCES AN EIGHT-YEAR EXTENSION OF THE DISTRIBUTION AGREEMENT WITH KAMADA IN THE US FOR KEDRAB® KMDA: Amendment and Extension of Kedrab® U.S. Distribution Agreement to Generate at Least $180 Million Over First Four Years… Kamada Announces its Largest Commercial Agreement; A Strategic Engagement with Kedrion for U.S. Distribution of KEDRAB® including $180 Million of Revenues Over First Four Years KMDA: $37.9 Million in 3Q23 Revenues; Closes $60 Million Private Placement with FIMI Opportunity Funds… Kamada Reports Significant Increase in Sales and Profitability in the Third Quarter and Nine Month 2023; Reiterates 2023 Revenue and Profitability Guidance Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2023 Financial Results and Host Conference Call on November 13, 2023 Kamada Announces Recent Achievements with CYTOGAM® including Availability of Product Manufactured by the Company for U.S Commercial Sale and Presentation of New Clinical Data
